Trials / Completed
CompletedNCT02692703
A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)
A Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (MAGELLAN-2)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and efficacy of 12 weeks of treatment of ABT-493/ABT-530 (glecaprevir/pibrentasvir) in adults who are post primary orthotopic liver or renal transplant with chronic hepatitis C virus (HCV) infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | glecaprevir/pibrentasvir | Tablet; glecaprevir coformulated with pibrentasvir |
Timeline
- Start date
- 2016-04-22
- Primary completion
- 2017-04-13
- Completion
- 2017-06-29
- First posted
- 2016-02-26
- Last updated
- 2021-07-13
- Results posted
- 2018-04-04
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02692703. Inclusion in this directory is not an endorsement.